Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 6/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853070 | 1.00 | SORT1 (0.46) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL30294825 | 0.89 | SORT1 (0.51) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL22853177 | 0.89 | SORT1 (0.51) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL22853430 | 0.88 | SORT1 (0.45) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL30294432 | 0.88 | SORT1 (0.45) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL22853425 | 0.88 | SCN8A (0.47) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL29382977 | 0.88 | SCN8A (0.47) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL22853186 | 0.86 | SORT1 (0.46) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL30294526 | 0.86 | SORT1 (0.46) | SORT1NTRK1NTRK2KDM4EHPGD | |
| SCHEMBL22853181 | 0.84 | SORT1 (0.52) | SORT1NTRK1NTRK2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | SORT1 3573/4885NTRK1 1014/4885NTRK2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.